Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary

NCT02590055 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02590055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02590055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2015
Completion date
September 30, 2019
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma of unknown primary